Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$5.95 USD
+0.12 (2.06%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.96 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRDA 5.95 +0.12(2.06%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Other News for TRDA
Entrada Therapeutics (TRDA) Hits Key Milestone in Duchenne Therapy Trials
Entrada Therapeutics GAAP EPS of -$1.04, revenue of $2M
Entrada Therapeutics Reports Second Quarter 2025 Financial Results | TRDA Stock News
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
Tracking Baker Brothers Portfolio - Q1 2025 Update